Milestone Pharmaceuticals(MIST)
搜索文档
Milestone Pharmaceuticals(MIST) - 2023 Q3 - Quarterly Report
2023-11-13 19:09
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38899 Milestone Pharmaceuticals Inc. (Exact Name of Registrant as Specified in its Charter) Québec Not appl ...
Milestone Pharmaceuticals(MIST) - 2023 Q2 - Quarterly Report
2023-08-10 19:28
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38899 Milestone Pharmaceuticals Inc. (Exact Name of Registrant as Specified in its Charter) Québec Not applicabl ...
Milestone Pharmaceuticals(MIST) - 2023 Q1 - Quarterly Report
2023-05-11 19:09
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38899 Milestone Pharmaceuticals Inc. (Exact Name of Registrant as Specified in its Charter) Québec Not applicab ...
Milestone Pharmaceuticals(MIST) - 2022 Q4 - Annual Report
2023-03-29 21:11
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-38899 Milestone Pharmaceuticals Inc. (Exact name of registrant as specified in its charter) Québec Not applicable ( ...
Milestone Pharmaceuticals (MIST) Investor Presentation - Slideshow
2023-03-17 02:16
Corporate Overview March 2023 Forward Looking Statement The Presentation contains forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, as amended. Words such as ‘‘aim,’’ ‘‘anticipate,’’ ‘‘assume,’’ ‘‘believe,’’ ‘‘contemplate,’’ ‘‘continue,’’ ‘‘could,’’ ‘‘design,’’ ‘‘due,’’ ‘‘estimate,’’ ‘‘expect,’’ ‘‘goal,’’ ‘‘intend,’’ ‘‘may,’’ ‘‘objective,’’ ‘‘plan,’’ ‘‘predict,’’ ‘‘positioned,’’ ‘‘potential,’’ ‘‘project,’’ ‘‘seek,’’ ‘‘should, ...
Milestone Pharmaceuticals (MIST) Investor Presentation - Slideshow
2022-04-06 01:18
Corporate Overview March 24, 2022 Joseph Oliveto Chief Executive Officer Disclaimers The Presentation contains forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, as amended. Words such as ''aim,'' ''anticipate,'' ''assume,'' ''believe,'' ''contemplate,'' ''continue,'' ''could,'' ''design,'' ''due,'' ''estimate,'' ''expect,'' ''goal,'' ''intend,'' ''may,'' ''objective,'' ''plan,'' ''predict,'' ''positioned,'' ''potential,'' ''p ...
Milestone Pharmaceuticals (MIST) Investor Presentation - Slideshow
2019-11-23 03:01
| --- | --- | --- | --- | --- | --- | |-------------------------|---------------|-------|-------|-------|-------| | | | | | | | | | | | | | | | Corporate Overview – | November 2019 | | | | | | | | | | | | | | | | | | | | Joseph Oliveto | | | | | | | Chief Executive Officer | | | | | | Disclaimers This Presentation contains forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, as amended. In some cases, you can identify forward-lo ...
Milestone Pharmaceuticals (MIST) Presents At 2019 Jefferies Global Healthcare Conference - Slideshow
2019-06-08 03:59
| --- | --- | --- | --- | --- | |-------------------------|-------|-------|-------|-------| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | Joseph Oliveto | | | | | | Chief Executive Officer | | | | | Disclaimers This Presentation contains forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, as amended. In some cases, you can identify forward-looking statements by terminology such as ''aim,'' ''anticipate,'' ''assu ...